Navigation Links
Schizophrenic in Medical News

Improving the prognosis for schizophrenic disorders

Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage. It is hoped that this will improve the prognosis, which has often been unfavorable. In the latest edition of Deutsches rzteblatt International ( Dtsch Arztebl Int 2008; 105[30]: 5...

Cognitive rehabilitation holds promise for schizophrenic brain function improvements

Study had shown that it is possible to improve the brain functions of schizophrenic// patients through cognitive rehabilitation programs. Researchers from Washington University in St. Louis have suggested that memorization strategies used by normal people to remember things may be useful for s...

Music to help schizophrenic patients

Scientists have found that in addition to schizophrenic patients being given medical care, music, as a therapy, can bring about changes in their general sense of well being, mental state and social activities.// Since 1950s music had been used as a therapy for people with serious mental disord...

Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009

...comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Columbia leads national effort to develop early intervention for schizophrenia

...ders by dramatically slowing progression; reducing disability, mortality, and the expense of care; and increasing recovery. The Recovery After Initial schizophrenic Episode (RAISE) study, funded at $9.9 million for two years, has the potential to be extended to six years and a total of $21.3 million if certain mil...

Study finds cancer is the second most frequent cause of death in individuals with schizophrenia

...tify characteristics that might help predict which schizophrenic patients are likely to develop cancer. The rese...he general population (56.3 vs. 33.0%). In female schizophrenic patients, the risk of death due to breast cancer w...ing less attention to symptoms; the difficulty for schizophrenic patients to benefit from optimum treatment; and le...

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications

...including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status

...lts from its first Phase 3 clinical trial of AZ-004 in 344 acutely agitated schizophrenic patients. The study design was similar to the clinical trial outlined abov...o loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive ...

Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009

...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Common Genes Link Bipolar Disorder, Schizophrenia

...to the study, published in this week's edition of The Lancet , brothers or sisters of people with these conditions were nine times more likely to be schizophrenic and had eight times the risk of developing bipolar disorder. The odds were less steep but still high for half-siblings. Brothers and sisters with...

Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices

...ties because Zyprexa is not approved for any use in that patient population in addition to the fact that the typical residents of these homes were not schizophrenic or bipolar. "Our clients questioned their superiors about the legality of Lilly's Zyprexa marketing practices," explained Deming, "but they were inst...

Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa

...n place of the management of the manifestations of psychotic disorders. Also in Nov. 2000, FDA approved Zyprexa for maintaining treatment response in schizophrenic patients who had been stable for approximately eight weeks and were then followed for a period of up to eight months. Zyprexa has never been approved...

Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts

... Alexza has five product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, has completed one Phase 3 clinical trial and enrolled a second Phase 3 trial. The Company has completed its end-of-Phase...

Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates

...from its first Phase 3 clinical trial of AZ-004 in schizophrenic patients with acute agitation. Both the 5 mg and t...rability and pharmacokinetic study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in schizophrenic patients with acute agitation. Alexza completed an...

Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008

... Alexza has five product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, has completed one Phase 3 clinical trial and enrolled a second Phase 3 trial. The Company has completed its end-of-Phase...

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

... including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...

Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.

...hich is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients. Mr. Williams will continue to serve as the ...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...

Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Alexza's Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder

...ncluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...

Alexza to Webcast Investor and Analyst Day Presentations

...), and discuss the role that AZ-004 may play in treating acute agitation in schizophrenic or bipolar disorder patients. Alexza senior management will also provide an...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...

First do no harm? UH prof taking opposite approach to treat asthma

...nd the skin irritant retinoic acid is used to treat acne. Additionally, there has been research into using antipsychotic drugs traditionally used for schizophrenic patients to decrease the incidence of Alzheimers disease by suppressing the dopamine system, which is hypoactive in such neurodegenerative diseases. ...

Restrictive Prescription Drug Policies Hurt Schizophrenics

... study authors said. "Given the tremendous variation in individual responses to drugs as well as the devastating impact of treatment disruptions on schizophrenic patients, a policy that pushes all patients toward a limited number of preferred drugs may do more harm than good," Soumerai said. "It would be much b...

Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008

...s of its Phase IIa clinical trial of AZ-004 in 129 schizophrenic patients with acute agitation. In that trial, the ...nistering the injection. Alexza believes that many schizophrenic and bipolar patients can make informed decisions r...cting, noninvasive treatment of acute agitation in schizophrenic and bipolar patients. Conference Call At 5:00 p....

FDA Approves First Anti-Psychotic for Kids

...erdal and other drugs that are approved for treating these conditions in adults," Laughren said. The FDA based its approval for using the drug with schizophrenic adolescents on the results of two short-term trials. Patients taking the drug had fewer symptoms, including fewer hallucinations and less delusional t...

NIH Awards Emory $3.6 Million for Schizophrenia Gene Research

... Emory University School of Medicine a $3.6 million research grant to test schizophrenic patients for a recently discovered variation in the human genome. The proje...w major research centers, the Emory project will screen a collection of 500 schizophrenic patients and 500 controls (individuals without schizophrenia) for CNV throu...

Brain Cells Activity: New Treatment Target for Psychiatric Diseases

...tered signaling pathway for neuregulin-1 and ErbB4 genes in the brains of schizophrenics. Dr. Mei's findings show that these factors associated with a schizophrenic brain have at least two places to act. "There is a ton of evidence that when inhibitory synapses, such as GABA, go wrong, the symptoms of mice...

Marijuana can Trigger Psychotic Symptoms, New Study Finds

...healthy subjects experienced psychotic symptoms when given the drug. While the doctors expected to see marijuana improve the conditions of their schizophrenic subjects—since their patients reported that the drug calmed them—they found that the reverse was true. "I was surprised by the results," said Dr...
Other Tags
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
(Date:12/21/2014)... 2014 SCI explores disability ... and systemic barriers for disabled athletes with Aaron ... has a condition called juvenile macular degeneration, where he ... he adapted his athletic ambitions to his vision and ... triathlon to pioneer the way for other blind and ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... blood clots from using testosterone products such as AndroGel ... that the male hormone testosterone may increase the risk ... in the Proceedings of the National Academy of Sciences ... of male rats with naturally occurring colon cancer. Dr. ...
(Date:12/21/2014)... December 21, 2014 The Oncology Institute of ... the Santa Ana and Whittier offices. The Hope for the ... lives of patients and their families during the holiday season. ... to approximately 70 children between both offices. This event continues ... of Target’s community service team, store managers and assistant managers ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, ... The business has drastically cut prices to all its ... until Jan. 30, 2015. Many of the hottest styles ... dresses, lace dresses, and more. , A spokesman for ... day. Whether A-line princess prom dresses or sweetheart chiffon ...
Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
Other Contents